Access to Addiction Pharmacotherapy in Private Health Plans

Abstract

Background An increasing number of medications are available to treat addictions. To understand access to addiction medications, it is essential to consider the role of private health plans. To contain medication expenditures, most U.S. health plans use cost-sharing and administrative controls, which may impact physicians' prescribing and patients' use of addiction medications. This study identified health plan approaches to manage access to and utilization of addiction medications (oral and injectable naltrexone, acamprosate, and buprenorphine). Methods Data are from a nationally representative survey of private health plans in 2010 (n=385 plans, 935 products; response rate 89%), compared to the same survey in 2003. The study assessed formulary inclusion, prior authorization, step therapy, overall restrictiveness, and if and how health plans encourage pharmacotherapy. Results Formulary exclusions were rare in 2010, with acamprosate excluded most often, by only 9% of products. Injectable naltrexone was covered by 96% of products. Prior authorization was common for injectable naltrexone (85%) and rare for acamprosate (3%). Step therapy policies were used only for injectable naltrexone (41%) and acamprosate (20%). Several medications were often on the most expensive tier. Changes since 2003 include fewer exclusions, yet increased use of other management approaches. Most health plans encourage use of addiction pharmacotherapy, and use a variety of methods to do so. Conclusions Management of addiction medications has increased over time but it is not ubiquitous. However, health plans now also include all medications on formularies and encourage providers to use them, indicating they value addiction pharmacotherapy as an evidence-based practice.

The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance

“…Rates of methadone treatment were low among the privately insured, possibly as a result of methadone not being a covered service. 27 We found that the number of PCPs prescribing buprenorphine in Medicaid increased as did the number of people receiving buprenorphine from PCPs. This finding presents compelling evidence that PCP involvement in OUD care is increasing, though it remains concentrated in a relatively small number of providers.…”

“…MOUD initiation rates were slightly higher among Medicaid enrollees compared to privately insured individuals. Rates of methadone treatment were low among the privately insured, possibly as a result of methadone not being a covered service 27 …”

Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017

“…Previous research has documented that many state Medicaid programs and large private health plans place restrictions on coverage of OUD medications. 14,15 Likewise, while changes in provider guidelines and education, dosing regulations and other policies have been associated with reductions in opioid prescribing for pain, 6 insurance coverage restrictions such as prior authorization (PA) (i.e., enrollee must obtain plan approval before coverage is granted) or step therapy (ST) (i.e., enrollees must document prior trial of a lower-cost medication before receiving coverage for a higher-cost medication) could also be tools used by insurers to limit access to opioids.…”

Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014

“…Given the high rate of relapse for people with OUDs, medications such as methadone, buprenorphine, and extended-release naltrexone are considered front-line treatment and have been shown to be both effective and cost-effective (American Society of Addiction Medicine 2015; Fullerton et al 2014; Gastfriend 2011; Mattick et al 2014; Reif et al 2016; Schackman et al 2012; Thomas et al 2014). Methadone has been available for decades, yet for treatment of OUDs is only available in “opioid treatment programs” (OTPs) subject to specific federal regulations regarding the dispensing of opioid agonist medications.…”